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Validity of the patient health questionnaire-9 to screen for depression in a
high-HIV burden primary healthcare clinic in Johannesburg, South Africa
Abstract

Background Integration of depression screening into primary care may increase access to mental health
services in sub-Saharan Africa, but this approach requires validated screening instruments. We sought to
validate the Patient Health Questionnaire-9 (PHQ-9) as a depression screening tool at a high HIV-burden
primary care clinic in Johannesburg, South Africa. Methods We conducted a validation study of an
interviewer-administered PHQ-9 among 397 patients. Sensitivity and specificity of the PHQ-9 were
calculated with the Mini International Neuropsychiatric Interview (MINI) as the reference standard; receiver
operating characteristic (ROC) curve analyses were performed. Results The prevalence of depression was
11.8%. One-third of participants tested positive for HIV. HIV-infected patients were more likely to be
depressed (15%) than uninfected patients (9%; p=0.08). Using the standard cutoff score of ¿10, the PHQ-9
had a sensitivity of 78.7% (95% CI: 64.3-89.3) and specificity of 83.4% (95% CI: 79.1-87.2). The area under
the ROC curve was 0.88 (95% CI: 0.83-0.92). Test performance did not vary by HIV status or language. In
sensitivity analyses, reference test bias associated with the MINI appeared unlikely. Limitations We were
unable to conduct qualitative work to adapt the PHQ-9 to this cultural context. Conclusion This is the first
validation study of the PHQ-9 in a primary care clinic in sub-Saharan Africa. It highlights the potential for
using primary care as an access point for identifying depressive symptoms during routine HIV testing. The
PHQ-9 showed reasonable accuracy in classifying cases of depression, was easily implemented by lay health
workers, and is a useful screening tool in this setting.
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INTRODUCTION
Mental illness imposes an immense global disease burden, particularly in low and middleincome countries where access to mental health services is lacking (Kessler et al., 2009,
Becker and Kleinman, 2013). Major depressive disorder (MDD) is the second leading
contributor to years lived with disability (YLD) globally, and ranks within the top four
causes of YLDs in all regions worldwide (Vos et al., 2012). In sub-Saharan Africa more
than two-thirds of patients with severe mental illness are unable to access mental health care
and this number rises to approximately 80% for patients with moderate or mild mental
illness (Wang et al., 2007). To address these challenges, the integration of mental health
screening approaches in primary care has been suggested as a mode for increasing access to
care in low and middle-income settings (Collins et al., 2013, Tomlinson et al., 2009b).

NIH-PA Author Manuscript

The implementation of routine mental health screening in sub-Saharan African primary
health care (PHC) settings requires validated rapid screening instruments that can be easily
administered by lay healthcare workers in busy clinics (Freeman et al., 2005, Becker and
Kleinman, 2013). To our knowledge, brief depression screening tools have not been
validated for a general PHC context in sub-Saharan Africa. A limited number of validation
studies of depression screening tools have been conducted against diagnostic reference
standards in sub-Saharan African settings, but these studies have varied in their choice of
context, screening tool, and diagnostic measure, making the results difficult to apply to a
PHC context. (Andersen et al., 2011, Akena et al., 2012a, Akena et al., 2012b, Pence et al.,
2012, Chishinga et al., 2011, Monahan et al., 2009, Myer et al., 2008, Nakimuli-Mpungu et
al., 2012b, Spies et al., 2009, Adewuya et al., 2006, Akena et al., 2013). In particular, the
populations included in these studies, such as university students, household survey
participants, pregnant or postnatal women, or HIV-infected patients, are not easily
generalizable to a PHC population.

NIH-PA Author Manuscript

Depression is a common and debilitating comorbidity of HIV in sub-Saharan Africa. The
reported prevalence of depression in HIV-infected African adults in ranges from 8–60%,
several times greater than prevalence estimates in the general population (Ramirez-Avila et
al., 2012, Hughes et al., 2004, Kagee and Martin, 2010, Myer et al., 2008, Olley et al., 2004,
Lawler et al., 2011, Kinyanda et al., 2011, Nakimuli-Mpungu et al., 2011, NakimuliMpungu et al., 2012a, Tomlinson et al., 2009a). The relationship between MDD and HIV is
complex, as depression can be a risk factor for HIV acquisition as well as a consequence of
HIV infection (Smit et al., 2006, Simoni et al., 2011). However, MDD has long been
recognized as a predictor of negative clinical outcomes among people with HIV (Bing et al.,
2001, Simoni et al., 2011, Owe-Larsson et al., 2009, Lopes et al., 2012). Persons with
depression initiate anti-retroviral treatment (ART) at lower CD4 counts than people without
mental illness, and depressed patients are much less likely to adhere to ART than patients
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who are not depressed (Tegger et al., 2008, Gonzalez et al., 2011, Nakimuli-Mpungu et al.,
2012a, Kaharuza et al., 2006).
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Routine mental health screening in PHC settings, where most HIV-infected patients are
diagnosed and seek regular care, might be a valuable approach to identify both HIV-infected
and HIV-uninfected patients who require further mental health assessment. Routine
depression screening is recommended for HIV infected patients in high-resource settings
and can be an effective way to identify patients at risk for negative outcomes (Shacham et
al., 2009, Schumacher et al., 2012, O’Connor et al., 2009). Depressed HIV-infected patients
who receive treatment for mental health illness have improved ART adherence and
increased quality of life (Yun et al., 2005, Elliott et al., 2002). As interventions to increase
access to early ART are scaled up throughout sub-Saharan Africa and universal HIV
counseling and testing (HCT) becomes the norm, integration of mental health services and
HIV programs could be an important component of ensuring optimal care and treatment
utilization for these two highly comorbid conditions (Stein et al., 2005).

NIH-PA Author Manuscript

Here, we have conducted a validation study of an interviewer-administered brief screening
tool for depression, in a high HIV burden, low literacy PHC population in Johannesburg,
South Africa. We sought to validate the PHQ-9 as a depression screening tool compared to
the internationally validated Mini International Neuropsychiatric Interview (MINI) among
patients undergoing routine HCT in a primary care setting. We also sought to provide
additional evidence of the utility of the PHQ-9 among HIV-infected people in sub-Saharan
Africa.

METHODS
Ethical approvals
The Institutional Review Board at the University of North Carolina (No. 12–1730) and the
Human Research Ethics Committee at the University of Witwatersrand (No. M120725)
approved this study.
Study setting and population

NIH-PA Author Manuscript

Witkoppen Health and Welfare Centre (WHWC) is a high-volume primary health care clinic
in northern Johannesburg, South Africa that provides comprehensive services predominantly
to persons living in densely populated peri-urban formal and informal settlements. At
WHWC, every clinic client with an unknown HIV status or with a negative HIV test more
than three months old routinely undergoes opt-out HCT.
The study population comprised a randomly selected subset of patients who were
undergoing routine HCT at WHWC between September 2012 and April 2013. Participants
were eligible for enrollment if they presented at WHWC for any reason, were at least 18
years old, not pregnant by self-report, could communicate in one of 5 common languages
used by interviewers (English, isiZulu, isiXhosa, seSotho, seTswana), and were able to
provide informed consent. Persons found to be experiencing acute suicidal ideation during
the PHQ-9 were excluded and referred for immediate assistance.
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Measures
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PHQ-9—The PHQ-9 is a 9-item depression screening tool that determines the presence and
frequency of the 9 core depressive symptoms identified in the DSM-IV over the previous 2
weeks. This tool has been widely utilized in Western settings and more recently in subSaharan Africa (Pence et al., 2012, Monahan et al., 2009, Adewuya et al., 2006, Akena et
al., 2013). Scores range from 0–27, with a score of 10 or higher typically used to indicate the
presence of a depressive disorder that would benefit from treatment. While the PHQ-9 was
developed to be self-administered, interviewer-administration has yielded similar results
(Pinto-Meza et al., 2005).
MINI—The MINI International Neuropsychiatric Interview (MINI) is a short, structured
diagnostic interview for major psychiatric disorders. The MINI served as the reference
standard in this study (Sheehan et al., 1998). The MINI is a reliable and valid diagnostic tool
that has been used successfully in South African populations (Myer et al., 2008, Olley et al.,
2004). We used the MINI modules for major depressive disorder (MDD), anxiety disorders
(generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress
disorder), suicidality, and bipolar disorder.

NIH-PA Author Manuscript

Study Procedures
Eligible patients were selected randomly for recruitment each day. Patients were recruited
after clinic registration but prior to undergoing HCT. After providing informed consent, the
patient completed the screening interview, including the PHQ-9, with a trained layinterviewer. Questions about substance abuse and knowledge of HIV status (from prior
testing experiences) were also included in the questionnaire. Socio-demographic information
and clinical information was obtained from the patient’s WHWC clinic file. Due to low
literacy in the study population, the questionnaire was administered by the interviewer and
responses were recorded on a paper form. The questionnaire was translated and conducted in
5 common languages (English, isiZulu, isiXhosa, seSotho, seTswana).

NIH-PA Author Manuscript

After the screening interview, participants immediately completed the MINI interview with
a second study team member who was blinded to the results of the PHQ-9. The MINI
interview was conducted by health care professionals trained in use of the instrument. The
MINI was administered in the same language as the screening interview; an interpreter was
used when needed. Translations of the MINI were completed in the same languages used for
the screening tools and these standard translations were used when needed.
Study data were collected and managed using Research Electronic Data Capture (REDCap)
tools hosted at the University of North Carolina, Chapel Hill (Harris et al., 2009).
Analyses
A positive screen for probable depression was defined as a score ≥10 on the PHQ-9 (Pence
et al., 2012, Adewuya et al., 2006, Akena et al., 2013). Test characteristics including
sensitivity, specificity, and categorical likelihood ratios for the PHQ-9 were calculated
relative to a diagnosis of a current major depressive episode (MDE) on the MINI. A range of
cut-off scores (Data presented for cut-off scores of 8, 10, and 12) was considered for the
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PHQ-9. Categorical likelihood ratios were calculated for the standard scores of ≥5 (mild
depression/anxiety), ≥ 10 (moderate depression/anxiety), ≥ 15 (moderately severe
depression/severe anxiety), and ≥20 (severe depression). Post-test probabilities (analogous
to positive predictive values for a dichotomous test) were calculated for a range of
prevalence values of depression using categorical likelihood ratios. Receiver operating
characteristic (ROC) plots were graphed and the area under the curve (AUC) is reported.
Sensitivity analysis was conducted to assess the possible bias in PHQ-9 test performance
produced by misclassification of MDE by the MINI. Varying combinations of sensitivity
and specificity of the MINI reference standard were considered. In conditional independence
scenarios, which did not assume any relationship between a patient’s score on the PHQ-9
and their score on the MINI, MINI sensitivity was varied from 0.75 to 1.00 and specificity
from 0.97 to 1.00. In conditional dependence scenarios, it was theorized that patients who
underreported depressive symptoms on the PHQ-9 might also underreport on the MINI. For
the conditional dependence assessments, a range of reduced sensitivities of the MINI was
considered for the population who screened negative on the PHQ-9. Stata version 12
(College Station, TX) was used for all analyses.

NIH-PA Author Manuscript

RESULTS
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Between September 2012 and April 2013, 397 persons provided informed consent to
participate in this study. Participants had a median age of 35 years (IQR: 28–46 years) and
most were female (60%). About half of the participants were from South Africa (48%) and
more than a third were from Zimbabwe (37%). Nearly 60% were employed and 30%
reported drinking alcohol (Table 1). Of the 397 participants, 257 (64.7%) tested negative for
HIV on the enrollment date or within the previous 2 weeks and 113 (28.5%) tested positive
at enrollment or were not tested because they told the HIV counselor that they knew their
positive status and were enrolled in HIV care at another clinic (n=9). About two-thirds of
patients (65%) rated their general health status as good, very good, or excellent, while the
remainder reported poor or fair health. Compared to patients who were not depressed,
patients with depression reported poor or fair health more often (p<0.0001) and were more
likely to be female (p=0.06) and HIV-infected (p=0.08). Other demographic characteristics
were similar among depressed and not depressed patients. According to the PHQ-9, 44% of
the participants reported no depression (PHQ9= 0–4), 32% reported mild depression
(PHQ9=5–9), 18% reported moderate depression (PHQ9=10–14), 5% reported moderately
severe depression (PHQ9=15–19), and 1% reported very severe depression (PHQ9≥20).
PHQ-9
Of the 397 persons completing the MINI, 47 (11.8%) met the diagnostic criteria for a current
MDE on the MINI. Of the 47 patients, 19 (40.4%) were experiencing a comorbid anxiety
disorder and 3 (0.76%) met criteria for bipolar spectrum disorder. The most common
comorbid anxiety disorders were generalized anxiety disorder (GAD) and post-traumatic
stress disorder (PTSD). Compared to the MINI, the PHQ-9 performed modestly in this
population. Of the 47 persons meeting criteria for MDE, 37 had a positive PHQ-9
depression screen with the standard cut-off score of 10 or higher, yielding a sensitivity of
78.7% (95% CI: 64.3–89.3) (Table 2). Of the 350 participants who did not meet criteria for
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current major depression on the MINI, 292 had a negative depression screen on the PHQ-9,
corresponding to a specificity of 83.4% (95% CI: 79.1–87.2). An alternate PHQ-9 cut-off
score of 8 in the overall sample yielded a higher sensitivity of 87.2% (95% CI: 74.3–95.2)
and a lower specificity of 73.4% (95% CI: 68.5–78.0). A higher alternate cut-off score of 12
yielded a lower sensitivity of 55.3% (95% CI: 40.1–69.8) and a higher specificity of 89.1%
(95% CI: 85.4–92.2).
In ROC analysis, the PHQ-9 had an area under the curve (AUC) of 0.88 (95% CI: 0.83–
0.92), indicating moderately high accuracy (Figure 1). Likelihood ratios for the commonly
used PHQ-9 categories representing mild (5–9), moderate (10–14), moderately severe (15–
19), and severe (20–27) depression were 0.09, 0.50, 3.89, 6.77, and 22.3 respectively (Table
3). Post-test probabilities for these categories were calculated for a range of pre-test
probability (prevalence) values (Figure 2). At the 11.8% prevalence of MDE seen in the
study population (indicated by vertical line, Figure 2), the post-test probability of depression
for a PHQ-9 score between 10–14 is 34.2%, for a score between 15–20 it is 47.5%, and for a
score higher than 20 it is 75%.

NIH-PA Author Manuscript

Among HIV-positive participants, 15.0% (n=17) met the criteria for MDE compared to
8.9% of the HIV-negative participants. The PHQ-9 performed similarly in the HIV-positive
and HIV-negative populations (Table 2). Among the 113 HIV-infected patients, the PHQ-9
yielded a slightly higher sensitivity and a lower specificity compared to the HIV-negative
population, although these estimates are imprecise as there were only 17 cases of MDE in
the HIV-infected group.
Misclassification of true MDE by the MINI was not likely to have produced substantial bias,
as shown by sensitivity analyses. All scenarios where conditional independence was
considered suggested that the true values of sensitivity and specificity of the PHQ-9 were
underestimated by the observed estimates. Corrected estimates for sensitivity of the PHQ-9
ranged from 0.84 to 0.99 and corrected estimates for specificity of the PHQ-9 ranged from
0.84 to 0.86. Conditional dependence, assessed by reducing the sensitivity of the MINI for
patients screening negative on the PHQ-9, only slightly changed the observed results.
Additionally, the performance of the PHQ-9 did not differ according to the language in
which the interview was conducted.

NIH-PA Author Manuscript

DISCUSSION
In this high HIV burden PHC population in Johannesburg, South Africa, the PHQ-9 showed
high accuracy in correctly classifying cases of current MDE (AUC 0.88) relative to the
reference standard MINI. At the standard cut-off score of 10, the PHQ-9 had moderately
high sensitivity and specificity in the study population. The performance of the PHQ-9 was
similar to that from a range of other settings outside of sub-Saharan Africa (Gilbody et al.,
2007, Manea et al., 2012). Compared to other studies within sub-Saharan Africa, the PHQ-9
performed slightly worse than it did among university students in Nigeria (Adewuya et al.,
2006) or HIV-infected persons in Uganda (Akena et al., 2013), but it performed significantly
better in this study than it did among HIV-infected patients in Cameroon (Pence et al.,
2012). To our knowledge, ours is the only diagnostic validation study of the PHQ-9
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conducted among a general PHC population in sub-Saharan Africa, and it underscores both
the importance of a primary care setting in this region as an access point for identifying
depression and as well an accurate tool to do so.
We found an 11.8% prevalence of MINI-defined current MDE in the overall study sample,
higher than previously found among the general population in South Africa. A nationally
representative household survey found that 4.9% of South Africans had suffered from MDE
in the previous 12 months, as measured by the World Health Organization’s (WHO)
Composite International Diagnostic Interview (CIDI) (Tomlinson et al., 2009a). We would
expect our estimate to be higher than the prevalence from a household survey as our sample
includes chronically ill and disenfranchised patients who are more likely to experience
mental illness.

NIH-PA Author Manuscript

The variation between our prevalence estimate and others from the region may also be
explained by other estimates deriving from differing screening instruments, some of which
have not been validated against diagnostic tools. Additionally, some other prevalence
estimates focus particularly on specific population subsets rather than the general
population. For example, among the HIV-infected subset of this population, depression
prevalence was 15%, comparable to other prevalence estimates of MDD among HIVinfected African persons in studies using diagnostic tools (range ~3–35%) (Adewuya et al.,
2006, Lawler et al., 2011, Nakimuli-Mpungu et al., 2012b, Myer et al., 2008, Akena et al.,
2013, Spies et al., 2009). The high prevalence of comorbid anxiety disorders, particularly
GAD and PTSD, among depressed patients in this population reiterates the need to assess
patients presenting with depressive symptoms for comorbid psychiatric diagnoses, which
can lead to increased psychiatric severity and treatment resistance (Kessler et al., 2005,
Gaynes et al., 1999).
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When evaluating the clinical utility of the PHQ-9 for depression screening and choosing an
ideal cut-off score for this setting, we considered the prevalence of depression in the
population, the benefits and harms of screening, and the resources available for screening
and follow-up. In our study context, a busy PHC clinic in a resource-scarce setting with one
part-time mental health professional, patients screened by lay-workers using the PHQ-9
would then be evaluated by a PHC clinician who could confirm that a clinical depression
exists and decide whether to begin treatment in the PHC setting or refer to a mental health
professional. In this scenario, the categorical likelihood ratios, which capture the magnitude
of depression, are particularly useful in prioritizing patients compared to the standard
dichotomous cut-off score alone. The standard score of 10 groups together all patients with a
score of 10 or higher-so those who have a score of 11 (moderate depression) and those who
have a score of 20 (severe depression) are considered the same, discarding valuable
information about the degree of illness. In contrast, the categorical likelihood ratios allow
the clinician to prioritize patients based on the magnitude of the depression score and the
post-test probability of disease for a particular value of the PHQ-9. By multiplying the
categorical likelihood ratio for a particular score by the pre-test odds of disease, a post-test
odds can be calculated and easily converted to a post-test probability (Sonis, 1999). A
patient with a PHQ-9 score of 11 at WHWC has a post-test probability of approximately
34% of being depressed as compared to a post-test probability of approximately 75% for a
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patient with a PHQ-9 score of 20. Using the categorical likelihood ratios would allow these
two patients with different likelihoods of depression to be prioritized accordingly for the
limited mental health resources available at WHWC. The categorical likelihood ratios also
allow decision-makers to adjust the pre-test probability value for different groups of patients
by taking into account factors such as medical history (e.g. HIV infection status) or
laboratory data, rather than only the overall prevalence of depression in the general clinic
population. In this more sophisticated approach, one standard cutoff score is not applicable
to all patients in a clinic, but rather the cutoff score differs depending on a number of
important variables specific to each patient.
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In choosing an ideal cut-off score for the PHQ-9, we also considered the relative cost of a
false negative versus a false positive result. In our study setting, where many patients were
coping with chronic diseases such as HIV, it might be reasonable to consider a false
negative, or missing a true case of depression, to be worse than a false positive. Patients with
chronic conditions and comorbid depression are at risk for a multitude of negative outcomes
including poor adherence to treatment and increased morbidity and mortality (Katon, 2011).
Therefore, identifying the maximum number of true depression cases might be considered a
priority, especially among HIV infected patients in whom treatment initiation and adherence
is a significant concern. This approach would come at the expense of a higher number of
false positive screens, creating a higher burden on the clinic to spend time and resources
evaluating patients who are not true depression cases. These choices are ultimately
dependent on the setting in which the tool is applied and the resources available for followup.
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The strengths and limitations of this study should be considered. The cultural construct of
depression or anxiety in our study setting is likely to be very different from the Western
settings in which the PHQ-9 was first developed. The version of the PHQ-9 used in this
study was the same as that used in Cameroon among HIV-infected patients, which had been
adapted slightly through focus group feedback in Cameroon (Pence et al., 2012). While we
were able to translate the PHQ-9 into local languages, we were unable to conduct additional
focus groups or qualitative interviews in our study setting that would have allowed us to
further adapt the PHQ-9 for culturally-relevant use in this context and ensure that the tool
was well understood by the study population. Although our results did not differ according
to the language in which the PHQ-9 was administered, such qualitative research might have
increased the diagnostic properties of the PHQ-9 in our study. We would encourage other
researchers to conduct preliminary qualitative work when adapting and optimizing screening
tools for use outside of the context in which the tool was originally developed and validated.
While the MINI was used as the reference standard in our study, it is imperfect, especially in
light of the cultural considerations discussed above. However, the MINI has been validated
against other diagnostic interviews, including the CIDI and the Structured Clinical Interview
for DSM Disorders (SCID) and has itself been used as a reference standard for the validation
of many other psychiatric scales (Sheehan et al., 1998). Misclassification or reference-test
bias with use of the MINI is likely to occur to some degree, and will depend partly on the
experience level of the interviewer. Given the rigorous DSM-IV criteria utilized in the
MINI, we believe that false positives will be rare, although false negatives or missing cases
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of true MDE is possible. This would have biased our measured estimates of PHQ-9
sensitivity and specificity downwards. Our sensitivity analyses were consistent with
observed estimates of sensitivity and specificity of the PHQ-9 being underestimated. Given
our observed data, a MINI specificity of anything less than 1 would suggest that the reported
sensitivity of the PHQ-9 is an underestimate of the true sensitivity. Our data were
inconsistent with a MINI specificity less than 0.97 because of the low number of MDE cases
among patients screening negative on the PHQ-9. An additional source of bias could have
arisen through interviewer-administration of the PHQ-9 as participants may be less likely to
report mental health symptoms to an interviewer due to fear of stigmatization. This could
lead to conditional dependence through lower sensitivity of the MINI among patients who
screen negative on the PHQ-9, but sensitivity analysis showed that this would only slightly
affect our observed estimates of PHQ-9 performance.
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Mental health screening in this study was conducted among patients prior to undergoing
HCT. The advantage to this approach is that it allowed us to evaluate the performance of
screening instruments among patients who were HIV-negative as well as the 28.5% of the
study population who tested HIV positive after their participation in this study. Because
patients received their HIV test results after depression screening, new knowledge of an HIV
diagnosis would not have influenced HIV infected patients to screen positive for depression
due to an acute adjustment disorder with a depression reaction. We recognize that the HIVinfected patients in this population are different from those engaging in ongoing HIV care
who have been coping with long-term knowledge of HIV status, and that the prevalence of
mental illness may differ at various time points in HIV care. Other research on depression
and HIV in sub-Saharan Africa has focused mostly on patients who are aware of their HIV
status rather than those who are testing for HIV. Our results contribute important
information to the field as the mental health of HIV-infected patients prior to HCT has not
been evaluated. Identifying patients with underlying depression as early as HCT could help
identify patients at risk of defaulting treatment or care early on. Ideally, we would screen
patients for mental health illness at several time points in HIV care, if resources for followup exist.
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The PHQ-9 performed reasonably well as a screening tool in this high HIV-burden South
African clinic population and was easily implemented by lay health workers. Our results
provide insight on how we can screen for and prioritize often overlooked and highly
prevalent depressive symptoms in low-resource PHC settings in sub-Saharan Africa. Such
an intervention might be especially useful for monitoring high-risk subsets of the population
such as HIV-infected people at risk for defaulting treatment, although further research will
be required to determine how screening for depression can contribute to improved clinical
outcomes. This study provides a framework for implementing depression screening
programs in resource-scarce sub-Saharan African contexts and establishes the PHQ-9 as a
useful screening instrument in these settings.

Acknowledgments
Role of the funding source This work was supported by the Triangle Community Foundation Gertrude B. Elion
Award, National Institute of Mental Health grant 5F30MH096664, and National Institutes of Health Office of the
Director, Fogarty International Center, Office of AIDS Research, National Cancer Center, National Heart, Blood,

J Affect Disord. Author manuscript; available in PMC 2015 October 01.

Cholera et al.

Page 10
and Lung Institute, and the NIH Office of Research for Women’s Health through the Fogarty Global Health
Fellows Program Consortium comprised of the University of North Carolina, John Hopkins, Morehouse and Tulane
(1R25TW009340-01) and the American Recovery and Reinvestment Act.

NIH-PA Author Manuscript

Financial support for REDCAP was provided by grant UL1RR025747 from the Clinical and Translational Science
Award program of the Division of Research Resources, National Institutes of Health.
The authors wish to thank the data collection team-Happiness Ndobe, Mpho Mbulaheni, Nonhlanhla Msimango,
Victor Lerato, and Josanne Adam. We thank Dr. Annelies Van Rie for her guidance and support in implementing
the study. We are also deeply grateful to the patients and staff at Witkoppen Health and Welfare Center.

References

NIH-PA Author Manuscript
NIH-PA Author Manuscript

ADEWUYA AO, OLA BA, AFOLABI OO. Validity of the patient health questionnaire (PHQ-9) as a
screening tool for depression amongst Nigerian university students. J Affect Disord. 2006; 96:89–
93. [PubMed: 16857265]
AKENA D, JOSKA J, MUSISI S, STEIN DJ. Sensitivity and specificity of a visual depression
screening instrument among HIV-positive individuals in Uganda, an area with low literacy. AIDS
Behav. 2012a; 16:2399–406. [PubMed: 22810893]
AKENA D, JOSKA J, OBUKU EA, AMOS T, MUSISI S, STEIN DJ. Comparing the accuracy of
brief versus long depression screening instruments which have been validated in low and middle
income countries: a systematic review. BMC Psychiatry. 2012b; 12:187. [PubMed: 23116126]
AKENA D, JOSKA J, OBUKU EA, STEIN DJ. Sensitivity and specificity of clinician administered
screening instruments in detecting depression among HIV-positive individuals in Uganda. AIDS
Care. 2013
ANDERSEN LS, GRIMSRUD A, MYER L, WILLIAMS DR, STEIN DJ, SEEDAT S. The
psychometric properties of the K10 and K6 scales in screening for mood and anxiety disorders in
the South African Stress and Health study. Int J Methods Psychiatr Res. 2011; 20:215–23.
[PubMed: 22113964]
BECKER AE, KLEINMAN A. Mental health and the global agenda. N Engl J Med. 2013; 369:66–73.
[PubMed: 23822778]
BING EG, BURNAM MA, LONGSHORE D, FLEISHMAN JA, SHERBOURNE CD, LONDON AS,
TURNER BJ, EGGAN F, BECKMAN R, VITIELLO B, MORTON SC, ORLANDO M,
BOZZETTE SA, ORTIZ-BARRON L, SHAPIRO M. Psychiatric disorders and drug use among
human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;
58:721–8. [PubMed: 11483137]
CHISHINGA N, KINYANDA E, WEISS HA, PATEL V, AYLES H, SEEDAT S. Validation of brief
screening tools for depressive and alcohol use disorders among TB and HIV patients in primary
care in Zambia. BMC Psychiatry. 2011; 11:75. [PubMed: 21542929]
COLLINS PY, INSEL TR, CHOCKALINGAM A, DAAR A, MADDOX YT. Grand challenges in
global mental health: integration in research, policy, and practice. PLoS Med. 2013; 10:e1001434.
[PubMed: 23637578]
ELLIOTT AJ, RUSSO J, ROY-BYRNE PP. The effect of changes in depression on health related
quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry. 2002; 24:43–7. [PubMed:
11814533]
FREEMAN M, PATEL V, COLLINS PY, BERTOLOTE J. Integrating mental health in global
initiatives for HIV/AIDS. Br J Psychiatry. 2005; 187:1–3. [PubMed: 15994563]
GAYNES BN, MAGRUDER KM, BURNS BJ, WAGNER HR, YARNALL KS, BROADHEAD WE.
Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients
with major depression? Gen Hosp Psychiatry. 1999; 21:158–67. [PubMed: 10378109]
GILBODY S, RICHARDS D, BREALEY S, HEWITT C. Screening for depression in medical settings
with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med. 2007;
22:1596–602. [PubMed: 17874169]
GONZALEZ JS, BATCHELDER AW, PSAROS C, SAFREN SA. Depression and HIV/AIDS
treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;
58:181–7. [PubMed: 21857529]

J Affect Disord. Author manuscript; available in PMC 2015 October 01.

Cholera et al.

Page 11

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

HARRIS PA, TAYLOR R, THIELKE R, PAYNE J, GONZALEZ N, CONDE JG. Research electronic
data capture (REDCap)--a metadata-driven methodology and workflow process for providing
translational research informatics support. J Biomed Inform. 2009; 42:377–81. [PubMed:
18929686]
HUGHES J, JELSMA J, MACLEAN E, DARDER M, TINISE X. The health-related quality of life of
people living with HIV/AIDS. Disabil Rehabil. 2004; 26:371–6. [PubMed: 15204489]
KAGEE A, MARTIN L. Symptoms of depression and anxiety among a sample of South African
patients living with HIV. AIDS Care. 2010; 22:159–65. [PubMed: 20390494]
KAHARUZA FM, BUNNELL R, MOSS S, PURCELL DW, BIKAAKO-KAJURA W, WAMAI N,
DOWNING R, SOLBERG P, COUTINHO A, MERMIN J. Depression and CD4 cell count among
persons with HIV infection in Uganda. AIDS Behav. 2006; 10:S105–11. [PubMed: 16802195]
KATON WJ. Epidemiology and treatment of depression in patients with chronic medical illness.
Dialogues Clin Neurosci. 2011; 13:7–23. [PubMed: 21485743]
KESSLER RC, AGUILAR-GAXIOLA S, ALONSO J, CHATTERJI S, LEE S, ORMEL J, USTUN
TB, WANG PS. The global burden of mental disorders: an update from the WHO World Mental
Health (WMH) surveys. Epidemiol Psichiatr Soc. 2009; 18:23–33. [PubMed: 19378696]
KESSLER RC, CHIU WT, DEMLER O, MERIKANGAS KR, WALTERS EE. Prevalence, severity,
and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.
Arch Gen Psychiatry. 2005; 62:617–27. [PubMed: 15939839]
KINYANDA E, HOSKINS S, NAKKU J, NAWAZ S, PATEL V. Prevalence and risk factors of major
depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda. BMC
Psychiatry. 2011; 11:205. [PubMed: 22208452]
LAWLER K, MOSEPELE M, SELOILWE E, RATCLIFFE S, STEELE K, NTHOBATSANG R,
STEENHOFF A. Depression among HIV-positive individuals in Botswana: a behavioral
surveillance. AIDS Behav. 2011; 15:204–8. [PubMed: 19821023]
LOPES M, OLFSON M, RABKIN J, HASIN DS, ALEGRIA AA, LIN KH, GRANT BF, BLANCO
C. Gender, HIV status, and psychiatric disorders: results from the National Epidemiologic Survey
on Alcohol and Related Conditions. J Clin Psychiatry. 2012; 73:384–91. [PubMed: 22053858]
MANEA L, GILBODY S, MCMILLAN D. Optimal cut-off score for diagnosing depression with the
Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ. 2012; 184:E191–6. [PubMed:
22184363]
MONAHAN PO, SHACHAM E, REECE M, KROENKE K, ONG’OR WO, OMOLLO O, YEBEI
VN, OJWANG C. Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living
with HIV/AIDS in western Kenya. J Gen Intern Med. 2009; 24:189–97. [PubMed: 19031037]
MYER L, SMIT J, ROUX LL, PARKER S, STEIN DJ, SEEDAT S. Common mental disorders among
HIV-infected individuals in South Africa: prevalence, predictors, and validation of brief
psychiatric rating scales. AIDS Patient Care STDS. 2008; 22:147–58. [PubMed: 18260806]
NAKIMULI-MPUNGU E, BASS JK, ALEXANDRE P, MILLS EJ, MUSISI S, RAM M,
KATABIRA E, NACHEGA J. Depression, Alcohol Use and Adherence to Antiretroviral Therapy
in Sub-Saharan Africa: A Systematic Review. AIDS and Behavior. 2012a; 16:2101–2118.
[PubMed: 22116638]
NAKIMULI-MPUNGU E, MOJTABAI R, ALEXANDRE PK, KATABIRA E, MUSISI S,
NACHEGA JB, BASS JK. Cross-cultural adaptation and validation of the self-reporting
questionnaire among HIV+ individuals in a rural ART program in southern Uganda. HIV AIDS
(Auckl). 2012b; 4:51–60. [PubMed: 22570575]
NAKIMULI-MPUNGU E, MUSISI S, KATABIRA E, NACHEGA J, BASS J. Prevalence and factors
associated with depressive disorders in an HIV+ rural patient population in southern Uganda. J
Affect Disord. 2011; 135:160–7. [PubMed: 21851986]
O’CONNOR EA, WHITLOCK EP, BEIL TL, GAYNES BN. Screening for depression in adult
patients in primary care settings: a systematic evidence review. Ann Intern Med. 2009; 151:793–
803. [PubMed: 19949145]
OLLEY BO, SEEDAT S, NEI DG, STEIN DJ. Predictors of major depression in recently diagnosed
patients with HIV/AIDS in South Africa. AIDS Patient Care STDS. 2004; 18:481–7. [PubMed:
15321019]

J Affect Disord. Author manuscript; available in PMC 2015 October 01.

Cholera et al.

Page 12

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

OWE-LARSSON B, SALL L, SALAMON E, ALLGULANDER C. HIV infection and psychiatric
illness. Afr J Psychiatry (Johannesbg). 2009; 12:115–28. [PubMed: 19582313]
PENCE BW, GAYNES BN, ATASHILI J, O’DONNELL JK, TAYONG G, KATS D, WHETTEN R,
WHETTEN K, NJAMNSHI AK, NDUMBE PM. Validity of an interviewer-administered patient
health questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. J Affect
Disord. 2012
PINTO-MEZA A, SERRANO-BLANCO A, PENARRUBIA MT, BLANCO E, HARO JM. Assessing
depression in primary care with the PHQ-9: can it be carried out over the telephone? J Gen Intern
Med. 2005; 20:738–42. [PubMed: 16050884]
RAMIREZ-AVILA L, REGAN S, GIDDY J, CHETTY S, ROSS D, KATZ JN, FREEDBERG KA,
WALENSKY RP, LOSINA E, BASSETT IV. Depressive Symptoms and Their Impact on Healthseeking Behaviors in Newly-diagnosed HIV-infected Patients in Durban, South Africa. AIDS
Behav. 2012
SCHUMACHER JE, MCCULLUMSMITH C, MUGAVERO MJ, INGLE-PANG PE, RAPER JL,
WILLIG JH, YOU Z, BATEY DS, CRANE H, LAWRENCE ST, WRIGHT C, TREISMAN G,
SAAG MS. Routine Depression Screening in an HIV Clinic Cohort Identifies Patients with
Complex Psychiatric Co-morbidities Who Show Significant Response to Treatment. AIDS Behav.
2012
SHACHAM E, NURUTDINOVA D, SATYANARAYANA V, STAMM K, OVERTON ET. Routine
screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care
STDS. 2009; 23:949–55. [PubMed: 19925308]
SHEEHAN DV, LECRUBIER Y, SHEEHAN KH, AMORIM P, JANAVS J, WEILLER E,
HERGUETA T, BAKER R, DUNBAR GC. The Mini-International Neuropsychiatric Interview
(M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for
DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl 20):22–33. quiz 34–57. [PubMed:
9881538]
SIMONI JM, SAFREN SA, MANHART LE, LYDA K, GROSSMAN CI, RAO D, MIMIAGA MJ,
WONG FY, CATZ SL, BLANK MB, DICLEMENTE R, WILSON IB. Challenges in addressing
depression in HIV research: assessment, cultural context, and methods. AIDS Behav. 2011;
15:376–88. [PubMed: 21046221]
SMIT J, MYER L, MIDDELKOOP K, SEEDAT S, WOOD R, BEKKER LG, STEIN DJ. Mental
health and sexual risk behaviours in a South African township: a community-based cross-sectional
study. Public Health. 2006; 120:534–42. [PubMed: 16684549]
SONIS J. How to use and interpret interval likelihood ratios. Fam Med. 1999; 31:432–7. [PubMed:
10367208]
SPIES G, KADER K, KIDD M, SMIT J, MYER L, STEIN DJ, SEEDAT S. Validity of the K-10 in
detecting DSMI-V-defined depression and anxiety disorders among HIV-infected individuals.
AIDS Care. 2009; 21:1163–8. [PubMed: 20024776]
STEIN DJ, SEEDAT S, EMSLEY RA, OLLEY BO. HIV/AIDS in Africa--a role for the mental health
practitioner? S Afr Med J. 2005; 95:167–8. [PubMed: 15832665]
TEGGER MK, CRANE HM, TAPIA KA, ULDALL KK, HOLTE SE, KITAHATA MM. The effect
of mental illness, substance use, and treatment for depression on the initiation of highly active
antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008; 22:233–
43. [PubMed: 18290749]
TOMLINSON M, GRIMSRUD AT, STEIN DJ, WILLIAMS DR, MYER L. The epidemiology of
major depression in South Africa: results from the South African stress and health study. S Afr
Med J. 2009a; 99:367–73. [PubMed: 19588800]
TOMLINSON M, RUDAN I, SAXENA S, SWARTZ L, TSAI AC, PATEL V. Setting priorities for
global mental health research. Bull World Health Organ. 2009b; 87:438–46. [PubMed: 19565122]
VOS T, FLAXMAN AD, NAGHAVI M, LOZANO R, MICHAUD C, EZZATI M, SHIBUYA K,
SALOMON JA, ABDALLA S, ABOYANS V, ABRAHAM J, ACKERMAN I, AGGARWAL R,
AHN SY, ALI MK, ALVARADO M, ANDERSON HR, ANDERSON LM, ANDREWS KG,
ATKINSON C, BADDOUR LM, BAHALIM AN, BARKER-COLLO S, BARRERO LH,
BARTELS DH, BASANEZ MG, BAXTER A, BELL ML, BENJAMIN EJ, BENNETT D,
BERNABE E, BHALLA K, BHANDARI B, BIKBOV B, BIN ABDULHAK A, BIRBECK G,
J Affect Disord. Author manuscript; available in PMC 2015 October 01.

Cholera et al.

Page 13

NIH-PA Author Manuscript
NIH-PA Author Manuscript

BLACK JA, BLENCOWE H, BLORE JD, BLYTH F, BOLLIGER I, BONAVENTURE A,
BOUFOUS S, BOURNE R, BOUSSINESQ M, BRAITHWAITE T, BRAYNE C, BRIDGETT L,
BROOKER S, BROOKS P, BRUGHA TS, BRYAN-HANCOCK C, BUCELLO C,
BUCHBINDER R, BUCKLE G, BUDKE CM, BURCH M, BURNEY P, BURSTEIN R,
CALABRIA B, CAMPBELL B, CANTER CE, CARABIN H, CARAPETIS J, CARMONA L,
CELLA C, CHARLSON F, CHEN H, CHENG AT, CHOU D, CHUGH SS, COFFENG LE,
COLAN SD, COLQUHOUN S, COLSON KE, CONDON J, CONNOR MD, COOPER LT,
CORRIERE M, CORTINOVIS M, DE VACCARO KC, COUSER W, COWIE BC, CRIQUI MH,
CROSS M, DABHADKAR KC, DAHIYA M, DAHODWALA N, DAMSERE-DERRY J,
DANAEI G, DAVIS A, DE LEO D, DEGENHARDT L, DELLAVALLE R, DELOSSANTOS A,
DENENBERG J, DERRETT S, DES JARLAIS DC, DHARMARATNE SD, DHERANI M, et al.
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a
systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2163–96.
[PubMed: 23245607]
WANG PS, AGUILAR-GAXIOLA S, ALONSO J, ANGERMEYER MC, BORGES G, BROMET EJ,
BRUFFAERTS R, DE GIROLAMO G, DE GRAAF R, GUREJE O, HARO JM, KARAM EG,
KESSLER RC, KOVESS V, LANE MC, LEE S, LEVINSON D, ONO Y, PETUKHOVA M,
POSADA-VILLA J, SEEDAT S, WELLS JE. Use of mental health services for anxiety, mood,
and substance disorders in 17 countries in the WHO world mental health surveys. Lancet. 2007;
370:841–50. [PubMed: 17826169]
YUN LW, MARAVI M, KOBAYASHI JS, BARTON PL, DAVIDSON AJ. Antidepressant treatment
improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir
Immune Defic Syndr. 2005; 38:432–8. [PubMed: 15764960]

NIH-PA Author Manuscript
J Affect Disord. Author manuscript; available in PMC 2015 October 01.

Cholera et al.

Page 14

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 1.

Receiver operating characteristic (ROC) curve for PHQ-9
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Figure 2.

Post-test probability for varying PHQ-9 categories, based on categorical likelihood ratios.
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Characteristics of the study population by depression (N=397)
Characteristic

Total study population*

Depression n (%) or median (IQR)

(n=397)

Yes (n=47)

No (n=350)

<=25

59 (14.9)

4 (8.5)

55 (15.7)

26–35

147 (37.0)

20 (42.6)

127 (36.3)

36–45

87 (21.9)

10 (21.3)

77 (22.0)

46–55

71 (17.9)

10 (21.3)

61 (17.4)

>55

33 (8.3)

3 (6.4)

30 (8.6)

Male

159 (40.1)

13 (27.7)

146 (41.7)

Female

236 (59.5)

34 (72.3)

202 (57.7)

Employed

230 (63.7)

29 (65.9)

201 (63.4)

Unemployed

131 (36.3)

15 (34.1)

116 (36.6)

South Africa

190 (49.9)

27 (57.4)

163 (48.8)

Other country

191 (50.1)

20 (42.6)

171 (51.2)

Any

118 (30.0)

13 (28.3)

105 (30.2)

None

276 (70.1)

33 (71.7)

243 (69.8)

Excellent

60 (15.2)

6 (13.0)

54 (15.5)

Very good

57 (14.5)

4 (8.7)

53 (15.2)

Good

139 (35.3)

10 (21.7)

129 (37.1)

Fair

79 (20.1)

13 (28.3)

66 (19.0)

Poor

59 (15.0)

13 (28.3)

46 (13.2)

Positive

113 (28.5)

17 (36.2)

96 (27.4)

Negative

257 (64.7)

23 (48.9)

234 (66.9)

27 (6.8)

7 (14.9)

20 (5.7)

Age (years)

Gender

Employment status

NIH-PA Author Manuscript

Country of birth

Alcohol use

Perceived health status

HIV status

NIH-PA Author Manuscript

Unknown†
*

Categories may not sum to the total because of missing data

†

Twenty seven participants are of unknown HIV status because they were either: 1) found to be either suicidal or mentally distressed during this
study so HCT was deferred (n=5, 1.3%); 2) they refused to test for HIV after undergoing pre-test counseling (n=6, 1.5%); or 3) the patient skipped
HCT (n= 16, 4%).
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37

26

≥10

≥12

38

58

93

312

292

257

TN

21

10

6

FN

55.3 (40.1–69.8)

78.7 (64.3–89.3)

87.2 (74.3–95.2)

Sensitivity (95% CI)

89.1 (85.4–92.2)

83.4 (79.1–87.2)

73.4 (68.5–78.0)

Specificity (95% CI)

15

14

11

≥8

≥10

≥12

15

28

39

FP

81

68

57

TN

6

3

2

FN

64.7 (38.3–85.8)

82.4 (56.6–96.2)

88.2 (63.6–98.5)

Sensitivity (95% CI)

84.4 (75.5–91.0)

70.8 (60.7–79.7)

59.4 (48.9–69.3)

Specificity (95% CI)

TP

20

17

12

Cut-off

≥8

≥10

≥12

22

28

48

FP

212

206

186

TN

11

6

3

FN

52.2 (30.6–73.2)

73.9 (51.6–89.8)

87.0 (66.4–97.2)

Sensitivity (95% CI)

90.6 (86.1–94.0)

88.0 (83.2–91.9)

79.5 (73.7–84.5)

Specificity (95% CI)

PHQ-9 test characteristics at various cut-off scores among HIV-negative patients only (n=257)

TP

Cut-off

TP= True positive, FP= False positive, TN= True negative, FN= False negative

*

41

≥8

FP

PHQ-9 test characteristics at various cut-off scores among HIV-positive patients only (n=113)

TP*

Cut-off

PHQ-9 test characteristics at various cut-off scores among whole study population (n=397)
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Likelihood ratios for commonly used PHQ-9 decision thresholds
Symptom severity

PHQ-9 category

Likelihood ratio

No depression

≤5

0.09

Mild depression

5–9

0.50

Moderate depression

10–14

3.89

Moderately severe depression

15–19

6.77

Severe depression

20–27

22.3
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